- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00231517
Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa
October 11, 2006 updated by: Institute of Child Health
Randomised Double blind placebo controlled cross over design study of the efficacy of morphine for inflammatory pain in children with Epidermolysis Bullosa
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, WC1N 1EH
- Great Ormond Street Hospital and the Institute of Child health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- children under 18 years epidermolysis wounds requiring dressing changes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard Howard, Prof, Institute of Child Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
October 3, 2005
First Submitted That Met QC Criteria
October 3, 2005
First Posted (Estimate)
October 4, 2005
Study Record Updates
Last Update Posted (Estimate)
October 12, 2006
Last Update Submitted That Met QC Criteria
October 11, 2006
Last Verified
October 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01MH17
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epidermylosis Bullosa
-
Castle Creek Pharmaceuticals, LLCCompletedDystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Simplex | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)United States
-
Krystal Biotech, Inc.CompletedDystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis BullosaUnited States
-
Krystal Biotech, Inc.CompletedDystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis BullosaUnited States
-
Castle Creek Biosciences, LLC.TerminatedEpidermolysis Bullosa Dystrophica, RecessiveUnited States
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos III; Universidad Carlos III Madrid (TERMeG); St John... and other collaboratorsUnknownEpidermolysis Bullosa Dystrophica, RecessiveSpain
-
Lenus Therapeutics, LLCTerminatedDystrophic Epidermolysis Bullosa | Junctional Epidermolysis BullosaUnited States
-
Holostem Terapie Avanzate s.r.l.IRCCS San Raffaele; University of Modena and Reggio EmiliaRecruitingJunctional Epidermolysis Bullosa Non-Herlitz TypeFrance, Italy
-
Krystal Biotech, Inc.RecruitingDystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis BullosaUnited States
-
Phoenicis TherapeuticsNot yet recruitingDystrophic Epidermolysis BullosaUnited States
-
Thomas Jefferson UniversityOnconova Therapeutics, Inc.RecruitingRecessive Dystrophic Epidermolysis BullosaUnited States
Clinical Trials on topical opiod
-
Universidad de AntioquiaINNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES... and other collaboratorsWithdrawnLeishmaniasis, CutaneousColombia
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Stanford UniversityUniversity of Pennsylvania; University of California, Davis; Oregon Health and... and other collaboratorsRecruiting
-
Abramson Cancer Center of the University of PennsylvaniaCompletedCutaneous T Cell LymphomaUnited States
-
Rhodes Pharmaceuticals, L.P.ORA, Inc.Completed
-
Amazentis SAproDERM GmbHCompleted
-
Amazentis SAproDERM GmbHCompletedErythema | Skin Inflammation | Sun Damaged SkinGermany
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Glia, LLCCompletedContact Lens Discomfort | Contact Lens-induced Corneal Disorder | Contact Lens Acute Red Eye | Contact Lens-induced Corneal Fluorescein StainingUnited States
-
Taro Pharmaceuticals USACompletedScalp PsoriasisUnited States